Effect of Exenatide on 24-Hour Blood Glucose Profile Compared with Placebo in Patients with Type 2 Diabetes

Study identifier:H8O-US-GWAW

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared with Placebo in Patients with Type 2 Diabetes Using Metformin or Metformin Plus a Thiazolidinedione

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

exenatide, Placebo

Sex

All

Actual Enrollment

30

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Oct 2005
Primary Completion Date: 01 Jun 2007
Study Completion Date: 01 Jun 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria